21
Participants
Start Date
October 31, 2013
Primary Completion Date
March 31, 2019
Study Completion Date
September 30, 2021
Panobinostat
\- Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.
Dexamethasone
Dexamethasone - oral dose on Days 1, 2, 4, 5, 8, 9, 11 and 12 followed by a 9-day rest period
Lenalidomide
Lenalidomide - daily oral dose on Days 1-14 followed by 7-day rest period
Bortezomib
Bortezomib - subcutaneous injection, on Days 1, 4, 8, and 11 followed by a 10-day rest period. At least 72 hours should elapse between bortezomib doses, but if needed an interval of 70 hours is permitted
Duke University Medical Center, Durham
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Collaborators (1)
Novartis
INDUSTRY
Dana-Farber Cancer Institute
OTHER